Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|May 15, 2019
8 New Findings in Bipolar Research
Author(s)Leo Robert
New genes linked with bipolar disorder, predominant polarity guides diagnosis and treatment, affective temperaments explain life events, and other developments here.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
3
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
4
New Preliminary Positive Data From Open-Label Extension of Phase 3 Study: Fasedienol for the Acute Treatment of Social Anxiety Disorder
5